Icosavax reports Q4 EPS (59c), consensus (59c)

Reports Q4 cash, cash equivalents, restricted cash, and short-term investments as of December 31 was $219.4M compared to $280.7 M as of December 31 . The amount as of December 31, includes $9.4M of net proceeds from the issuance of common shares under Icosavax’s at-the-market program. Icosavax currently expects its cash balance to be sufficient to fund operations through at least 2024.."We are proud of the progress we made in 2022, which included announcing positive interim results from our Phase 1/1b IVX-121 monovalent respiratory syncytial virus trial, followed by promising durability data at the six-month timepoint. Additionally, we initiated our Phase 1 trial for IVX-A12, a bivalent respiratory syncytial virus and human metapneumovirus VLP vaccine candidate," said Adam Simpson, Chief Executive Officer of Icosavax. "We have now completed dosing and plan to announce topline data for this Phase 1 trial in 2Q 2023, followed by the planned initiation of a Phase 2 study in the second half of this year. In February, our IVX-A12 program was further boosted when it was granted Fast Track designation by the FDA. These achieved and prospective milestones, along with a 12-month durability data readout from our IVX-121 Phase 1b extension trial around mid-year, mean that 2023 is shaping up to be an exciting period for Icosavax as we continue to work towards our vision."